Advertisement
News
Advertisement

Inovio Pharmaceuticals Subsidiary, VGX Animal Health, to Present at VetHealth Global 2011, June 14-17, 2011

Thu, 06/09/2011 - 1:35am
Bio-Medicine.Org

BLUE BELL, Pa., June 9, 2011 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that its majority-owned subsidiary, VGX Animal Health, Inc, will present at VetHealth Global 2011, an international animal health and nutrition business conference being held June 14-17, 2011, in Charlottetown, Prince Edward Island, Canada.  Douglas Kern, DVM, VGX Animal Health's Vice President of Business Development, will make the presentation.

Dr. Kern will highlight VGX Animal Health's focus on companion animal products including their development of VAH-1000 for cancer-associated anemia in dogs and, VAH-1050C for chronic renal failure in cats and VAH-1050D for chronic renal failure in dogs. Dr. Kern will also discuss VGX Animal Health's recent work with VAH-5000D, a very promising "universal" DNA cancer vaccine candidate for use in dogs.

Dr. Kern will speak at the conference during:Session VInnovation Spotlight: Early Stage Company PresentationsPresentation:  VGX Animal Health, GHRH & TERT Programs; Overview and Investment PotentialThursday, June 16, 20118:30AM – 10AMDouglas Kern, DVM, Vice President of Business Development, VGX Animal HealthAbout VGX Animal Health

VGX Animal Health is developing DNA-based therapies for companion and food animals utilizing proprietary plasmid-based DNA delivery and expression technology to optimize an animal's natural biological and immunological potential. The company is a majority-owned subsidiary of Inovio Pharmaceuticals, Inc.

About Inovio Pharmaceuticals, Inc.

Inovio is developing a new generation of vaccines, called DNA vaccines, to treat and prevent cancers and infectious diseases. Its SynCon™ vaccines are designed to provide broad cross-strain protection against

'/>"/>

SOURCE

Topics

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading